Tower Research Capital (TRC)’s Nymox Pharmaceutical Corp NYMX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-2,005
| Closed | -$381 | – | 6494 |
|
|
2023
Q2 | $381 | Buy |
2,005
+1,369
| +215% | +$539 | ﹤0.01% | 5667 |
|
|
2023
Q1 | $0 | Buy |
+636
| New | +$258 | ﹤0.01% | 6585 |
|
|
2022
Q1 | – | Sell |
-8,417
| Closed | -$11K | – | 6865 |
|
|
2021
Q4 | $11K | Buy |
+8,417
| New | +$13.4K | ﹤0.01% | 4496 |
|
|
2021
Q3 | – | Sell |
-17,431
| Closed | -$28K | – | 6367 |
|
|
2021
Q2 | $28K | Buy |
17,431
+12,421
| +248% | +$23K | ﹤0.01% | 3583 |
|
|
2021
Q1 | $11K | Sell |
5,010
-20,603
| -80% | -$54.3K | ﹤0.01% | 4336 |
|
|
2020
Q4 | $64K | Sell |
25,613
-67,756
| -73% | -$150K | ﹤0.01% | 2856 |
|
|
2020
Q3 | $230K | Buy |
93,369
+81,822
| +709% | +$238K | ﹤0.01% | 2445 |
|
|
2020
Q2 | $41K | Buy |
+11,547
| New | +$36.5K | ﹤0.01% | 3217 |
|
|
2020
Q1 | – | Sell |
-11,515
| Closed | -$25K | – | 4166 |
|
|
2019
Q4 | $25K | Buy |
11,515
+9,535
| +482% | +$18.8K | ﹤0.01% | 1794 |
|
|
2019
Q3 | $4K | Buy |
1,980
+298
| +18% | +$521 | ﹤0.01% | 3482 |
|
|
2019
Q2 | $2K | Sell |
1,682
-4,293
| -72% | -$7.51K | ﹤0.01% | 3347 |
|
|
2019
Q1 | $12K | Sell |
5,975
-2,145
| -26% | -$4.55K | ﹤0.01% | 2604 |
|
|
2018
Q4 | $11K | Sell |
8,120
-901
| -10% | -$1.65K | ﹤0.01% | 2423 |
|
|
2018
Q3 | $22K | Buy |
+9,021
| New | +$26.6K | ﹤0.01% | 2295 |
|
|
2018
Q1 | – | Sell |
-1,851
| Closed | -$6K | – | 4009 |
|
|
2017
Q4 | $6K | Buy |
1,851
+141
| +8% | +$514 | ﹤0.01% | 2838 |
|
|
2017
Q3 | $7K | Sell |
1,710
-273
| -14% | -$1.03K | ﹤0.01% | 3225 |
|
|
2017
Q2 | $8K | Buy |
+1,983
| New | +$8.14K | ﹤0.01% | 1753 |
|
|
2016
Q2 | – | Sell |
-73
| Closed | – | – | 5144 |
|
|
2016
Q1 | $0 | Sell |
73
-4,541
| -98% | -$10.7K | ﹤0.01% | 5161 |
|
|
2015
Q4 | $15K | Buy |
4,614
+3,875
| +524% | +$13K | ﹤0.01% | 1638 |
|
|
2015
Q3 | $3K | Sell |
739
-6,428
| -90% | -$15K | ﹤0.01% | 3194 |
|
|
2015
Q2 | $10K | Buy |
+7,167
| New | +$10K | ﹤0.01% | 2725 |
|
|
2014
Q4 | – | Sell |
-1,426
| Closed | -$6K | – | 4872 |
|
|
2014
Q3 | $6K | Buy |
+1,426
| New | +$6.99K | ﹤0.01% | 3200 |
|
|
2013
Q4 | – | Sell |
-184
| Closed | -$1K | – | 5018 |
|
|
2013
Q3 | $1K | Sell |
184
-418
| -69% | -$2.73K | ﹤0.01% | 4372 |
|
|
2013
Q2 | $3K | Buy |
+602
| New | +$3.05K | ﹤0.01% | 3348 |
|
Other funds holding NYMX
DDC
FCFC
CAM
ODIJL
Tower Research Capital (TRC)'s NYMX Position: Q3 2023 in Review
Tower Research Capital (TRC) sold out of Nymox Pharmaceutical Corp (NYMX) in Q3 2023, closing a stake of 2,005 shares — an estimated $381 sold.
Tower Research Capital (TRC) first reported a position in NYMX in Q2 2013 and held it in 24 quarters. The position peaked at $230K in Q3 2020. 5 funds tracked by Wall St. Rank hold NYMX as of Q3 2023.
- Tower Research Capital (TRC) reported no remaining Nymox Pharmaceutical Corp position as of Q3 2023 after selling out during the quarter.
- Tower Research Capital (TRC) sold 2,005 Nymox Pharmaceutical Corp shares in Q3 2023, an estimated $381.
- Tower Research Capital (TRC) first reported a position in Nymox Pharmaceutical Corp in Q2 2013 and held it in 24 quarters.
- Tower Research Capital (TRC)'s Nymox Pharmaceutical Corp position peaked at $230K in Q3 2020.
- 5 funds tracked by Wall St. Rank held Nymox Pharmaceutical Corp as of Q3 2023.
Based on Tower Research Capital (TRC)'s 13F filing for Q3 2023, filed 14 Nov 2023.